research is thriving at rush university. we’re invested in clinical, basic science and community-based research to advance our understanding of how diseases work and how best to treat them, which can improve care for patients at rush and around the globe.
here you can learn more about research efforts across rush: our laboratories and collaborations, facilities and services, and technologies for licensing.
rush partners with the university of chicago and other local hospital systems to help drive research breakthroughs and bring those discoveries into the real world to improve health.
every day rush university researchers are working to fight disease and improve health outcomes.
we embrace collaboration among our departments, as well as with other institutions and organizations.
our robust core facilities are available to faculty and offer opportunities for researchers outside rush.
we support faculty to propose studies, seek funding, negotiate contracts, secure patents and licensing, and much more.
we provide a wide range of services to researchers and research sponsors.
rush university helps connect faculty inventors to those interested in using their technologies.
we promote a culture of high-quality research, compliance and research integrity.
rush university is embarking on an exciting new phase of our research enterprise.
five junior faculty members at rush university will receive grant support for their research.
this four-part series looks at the perceptions of more than 2,000 americans, and the implications for coronavirus mitigation strategies.
researchers at rush university medical center, in collaboration with colleagues at other institutions, have revealed a new treatment target that may help change the outcome for patients at risk of aki.
researchers at rush university medical center have found that injecting tumors with influenza vaccines, including some fda-approved seasonal flu shots, turns cold tumors to hot, a discovery that could lead to an immunotherapy to treat cancer.
people who use methamphetamine have an increased risk of developing parkinson’s disease. a team of rush researchers is trying to understand why.
older people who experienced more hospitalizations and also had more alzheimer’s pathology in their brain experienced the fastest rates of cognitive decline, according to study results published in the oct. 15 online issue of the annals of neurology.